Publications

2018

Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis., E. Pronier; R.L. Bowman; J. Ahn; J. Glass; C. Kandoth; T.R. Merlinsky; J.T. Whitfield; B.H. Durham; A. Gruet; A.Varshini H. Somasundara; R. Rampal; A. Melnick; R.P. Koche; B.S. Taylor; R.L. Levine, Blood, 2018 Sep 20, 132, 12, p.1265-1278, (2018) PubMed

2017

Untangling the Web of Lymphoma Somatic Mutations., M. Teater; A. Melnick, Cell, 2017 10 05, 171, 2, p.270-272, (2017) PubMed

The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target., M.G. Cardenas; E. Oswald; W. Yu; F. Xue; A.D. MacKerell; A.M. Melnick, Clin Cancer Res, 2017 Feb 15, 23, 4, p.885-893, (2017) PubMed

The N-methyladenosine (mA)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells., L.P. Vu; B.F. Pickering; Y. Cheng; S. Zaccara; D. Nguyen; G. Minuesa; T. Chou; A. Chow; Y. Saletore; M. MacKay; J. Schulman; C. Famulare; M. Patel; V.M. Klimek; F.E. Garrett-Bakelman; A. Melnick; M. Carroll; C.E. Mason; S.R. Jaffrey; M.G. Kharas, Nat Med, 2017 Nov, 23, 11, p.1369-1376, (2017) PubMed

BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells., E. Valls; C. Lobry; H. Geng; L. Wang; M. Cardenas; M. Rivas; L. Cerchietti; P. Oh; S.Ning Yang; E. Oswald; C.W. Graham; Y. Jiang; K. Hatzi; X. Agirre; E. Perkey; Z. Li; W. Tam; K. Bhatt; J.P. Leonard; P.A. Zweidler-McKay; I. Maillard; O. Elemento; W. Ci; I. Aifantis; A. Melnick, Cancer Discov, 2017 05, 7, 5, p.506-521, (2017) PubMed

is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells., H. Kunimoto; A.Sophia McKenney; C. Meydan; K. Shank; A. Nazir; F. Rapaport; B. Durham; F.E. Garrett-Bakelman; E. Pronier; A.H. Shih; A. Melnick; J. Chaudhuri; R.L. Levine, Blood, 2017 Mar 30, 129, 13, p.1779-1790, (2017) PubMed

Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers., J.L. Glass; D. Hassane; B.J. Wouters; H. Kunimoto; R. Avellino; F.E. Garrett-Bakelman; O.A. Guryanova; R. Bowman; S. Redlich; A.M. Intlekofer; C. Meydan; T. Qin; M. Fall; A. Alonso; M.L. Guzman; P.J.M. Valk; C.B. Thompson; R. Levine; O. Elemento; R. Delwel; A. Melnick; M.E. Figueroa, Cancer Discov, 2017 08, 7, 8, p.868-883, (2017) PubMed

Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015., R.D. Gascoyne; B. Nadel; L. Pasqualucci; J. Fitzgibbon; J.E. Payton; A. Melnick; O. Weigert; K. Tarte; J.G. Gribben; J.W. Friedberg; J.F. Seymour; F. Cavalli; E. Zucca, Hematol Oncol, 2017 Dec, 35, 4, p.397-407, (2017) PubMed

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in - and -Mutant Acute Myeloid Leukemia., A.H. Shih; C. Meydan; K. Shank; F.E. Garrett-Bakelman; P.S. Ward; A.M. Intlekofer; A. Nazir; E.M. Stein; K. Knapp; J. Glass; J. Travins; K. Straley; C. Gliser; C.E. Mason; K. Yen; C.B. Thompson; A. Melnick; R.L. Levine, Cancer Discov, 2017 05, 7, 5, p.494-505, (2017) PubMed

Central role of myeloid MCPIP1 in protecting against LPS-induced inflammation and lung injury., Y. Li; X. Huang; S. Huang; H. He; T. Lei; F. Saaoud; X.Q. Yu; A. Melnick; A. Kumar; C.J. Papasian; D. Fan; M. Fu, Signal Transduct Target Ther, 2017, 2, , p.17066, (2017) PubMed